Sunovion Pharms Inc Drug Patent Portfolio
Sunovion Pharms Inc owns 1 orange book drug protected by 17 US patents Given below is the list of Sunovion Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9259423 | Method of treatment for mental disorders | 23 Nov, 2031 | Active |
| US9259423 | Method of treatment for mental disorders | 23 May, 2031 | Active |
| US9827242 | Method of treatment for mental disorders | 23 May, 2031 | Active |
| US8729085 | Pharmaceutical composition | 26 Nov, 2026 | Active |
| US8883794 | Pharmaceutical composition | 26 Nov, 2026 | Active |
| US9907794 | Pharmaceutical composition | 26 Nov, 2026 | Active |
| US8729085 | Pharmaceutical composition | 26 May, 2026 | Active |
| US8883794 | Pharmaceutical composition | 26 May, 2026 | Active |
| US9555027 | Pharmaceutical composition | 26 May, 2026 | Active |
| US9907794 | Pharmaceutical composition | 26 May, 2026 | Active |
| USRE45573 | Process for producing imide compound | 23 Dec, 2025 | Active |
| USRE45573 | Process for producing imide compound | 23 Jun, 2025 | Active |
| US9174975 | Remedy for integration dysfunction syndrome | 20 Aug, 2024 | Expired |
| US9174975 | Remedy for integration dysfunction syndrome | 20 Feb, 2024 | Expired |
| US9815827 | Agent for treatment of schizophrenia | 20 Feb, 2024 | Expired |
| US5532372 | Imide derivatives, and their production and use | 02 Jan, 2019 | Expired |
| US5532372 | Imide derivatives, and their production and use | 02 Jul, 2018 | Expired |
Latest Legal Activities on Sunovion Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sunovion Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 May, 2022 | US8883794 (Litigated) |
| Termination or Final Written Decision | 07 Dec, 2021 | US9815827 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2021 | US8729085 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Sep, 2021 | US9907794 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 May, 2021 | US9827242 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 May, 2021 | US9815827 |
|
Request for Trial Granted
Critical
| 09 Dec, 2020 | US9815827 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jul, 2020 | US9555027 |
| Petition Requesting Trial | 05 Jun, 2020 | US9815827 |
| Post Issue Communication - Certificate of Correction | 27 Jun, 2018 | US9907794 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2018 | US8883794 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 06 Mar, 2018 | US9907794 |
|
Recordation of Patent Grant Mailed
Critical
| 06 Mar, 2018 | US9907794 |
|
Email Notification
Critical
| 15 Feb, 2018 | US9907794 |
|
Issue Notification Mailed
Critical
| 14 Feb, 2018 | US9907794 |
Sunovion Pharms Inc's Drug Patent Litigations
Sunovion Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 18, 2017, against patent number US9555027. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Sumitomo Dainippon Pharma Co., Ltd. as the respondent. Click below to track the latest information on how companies are challenging Sunovion Pharms Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9815827 | June, 2020 |
Final Written Decision
(07 Dec, 2021)
| Sumitomo Dainippon Pharma Co., Ltd. et al. | Slayback Pharma LLC et al. |
| US9555027 | April, 2017 |
Terminated-Settled
(14 Aug, 2017)
| Sumitomo Dainippon Pharma Co., Ltd. | Par Pharmaceutical, Inc. |
Sunovion Pharms Inc's Family Patents
Sunovion Pharms Inc Drug List
Given below is the complete list of Sunovion Pharms Inc's drugs and the patents protecting them.
1. Latuda
Latuda is protected by 17 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9259423
(Pediatric)
| Method of treatment for mental disorders |
23 Nov, 2031
(6 years from now)
| Active |
| US9259423 | Method of treatment for mental disorders |
23 May, 2031
(6 years from now)
| Active |
| US9827242 | Method of treatment for mental disorders |
23 May, 2031
(6 years from now)
| Active |
| US8729085
(Pediatric)
| Pharmaceutical composition |
26 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8883794
(Pediatric)
| Pharmaceutical composition |
26 Nov, 2026
(1 year, 11 months from now)
| Active |
| US9907794
(Pediatric)
| Pharmaceutical composition |
26 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8729085 | Pharmaceutical composition |
26 May, 2026
(1 year, 5 months from now)
| Active |
| US8883794 | Pharmaceutical composition |
26 May, 2026
(1 year, 5 months from now)
| Active |
| US9555027 | Pharmaceutical composition |
26 May, 2026
(1 year, 5 months from now)
| Active |
| US9907794 | Pharmaceutical composition |
26 May, 2026
(1 year, 5 months from now)
| Active |
| USRE45573
(Pediatric)
| Process for producing imide compound |
23 Dec, 2025
(1 year, 4 days from now)
| Active |
| USRE45573 | Process for producing imide compound |
23 Jun, 2025
(6 months from now)
| Active |
| US9174975
(Pediatric)
| Remedy for integration dysfunction syndrome |
20 Aug, 2024
(3 months ago)
| Expired |
| US9174975 | Remedy for integration dysfunction syndrome |
20 Feb, 2024
(9 months ago)
| Expired |
| US9815827 | Agent for treatment of schizophrenia |
20 Feb, 2024
(9 months ago)
| Expired |
| US5532372
(Pediatric)
| Imide derivatives, and their production and use |
02 Jan, 2019
(5 years ago)
| Expired |
| US5532372 | Imide derivatives, and their production and use |
02 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Latuda's drug page